FDA 483 - Q-Med AB - March 27, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Q-Med AB in Uppsala, Sweden, a manufacturer of drug substance and drug product, received a Form FDA 483 with 11 observations. The inspection revealed significant deficiencies across contamination control, aseptic processing, environmental monitoring, quality systems, visual inspection, cleaning and disinfection, material control, and laboratory testing. These issues indicate a broad lack of adherence to cGMPs and inadequate quality oversight, posing risks to product quality and sterility.
ID · c2568e73-e2ad-4af7-8be3-5faa567bdf75